



**Table S1.** List of primers.

<b>Murine</b>	
<i>β-actin</i>	forward AGCCATGTACGTAGCCATCC, reverse CTCTCAGCTGTGGTGGTGAA
<i>Cyp1a1</i>	forward ACAGTGATTGGCAGAGATCG, reverse GAAGGGGAC-GAAGGATGAAT
<i>Cyp1b1</i>	forward TTCTCCAGCTTTTGCCTGT, reverse TAATGAAGCCGTCCTTGTCC
<i>Il10</i>	forward GAGAAGCATGGCCCAGAAATCAAG, reverse ATCACTCTTCAC-CTGCTCCACTGC
<i>Il1b</i>	forward TGACGGACCCCAAAAGATGAAGG, reverse CCACGGGAAAGA-CACAGGTAGC
<i>Il1ra</i>	forward TTGTGCCAAGTCTGGAGATG, reverse CAGCTGACTCAAA-GCTGGTG
<i>Il22</i>	forward CTGCCTGCTTCTCATTTGCCCTGTG, reverse GATGTACGGCTGCTG-GAAGTTGG
<i>Il25</i>	forward ACCACAACCAGACGGTCTTC, reverse ACACACACACAA-GCCAAGGA
<i>Il33</i>	forward TCCTGCCTCCCTGAGTACAT, reverse CACCTGGTCTTGCTCTTGGT
<i>Il6</i>	forward CCGGAGAGGAGACTTCACAG, reverse TCCACGATTTCACAGA-GAAC
<i>Il9</i>	forward TGACCAGCTGCTTGTGTCTC, reverse GTGGCATTGGTCAGCTG-TAA
<i>Ll37</i>	forward GGCGGTCACTATCACTGCTGCTG, reverse TCACTCGGAAC-CTCACAGACTTG
<i>Muc2</i>	forward GACTGCCGAGACTCTACAA, reverse CTT-GTGGGTGAGGTAGATGG
<i>Muc5ac</i>	forward CTGGACCTGGAGGTTGTATG, reverse CAGTAGTGAGGGTT-GGATGG
<i>Reg3b</i>	forward ATACCCTCCGCACGCATTAGTTG, reverse CTCCATTCCCATCCAC-CTCCATTG
<i>Reg3g</i>	forward AAGGTGAAGTTGCCAAGAAAG, reverse CATTGCTCCAC-TCCCATCC
<i>Tnfa</i>	forward CGAGTGACAAGCCTGTAGCC, reverse AAGAGAACCTGGGAG-TAGACAAG
<b>Bacteria</b>	
Actinobacteria	forward TACGGCCGCAAGGCTA, reverse CGCGGCCTATCAGCTTGTG
Bacteroidetes	forward GGARCATGTGGTTTAATTTCGATGAT, reverse AGCTGACGACAAC-CATGCAG
Proteobacteria	forward CCGCAAGGTTAAACTCAAAGGAA, reverse CAGA-CATGTCAAGGGTAGGTAAGG
BetaProteobacte- ria	forward GAGTGGCGAACGGGTGAGTAATA, reverse TCCGCGAG-CATGAGGTCTTG
Enterobacteri- aceae	forward CAGGTCGTCACGGTAACAAG, reverse GTGGTTCAGTTTCAG-CATGTAC
<i>E. coli</i>	forward CAAGTCATCATGGCCCTTAC, reverse CGGACTACGACGCAC-TTTAT
Firmicutes	forward GGAGYATGTGGTTTAATTCTGAAGCA, reverse AGCTGACGACAAC-CATGCAC
Clostridiaceae	forward AGCGTTGTCCGGATTTACTG, reverse CGCTTAC-CTCTCCGACACTC
Lactobacillaceae	forward TGGATGCCTTGGCACTAGGA, reverse AAATCTCCGGATCAAA-GCTTACTTAT
<i>L. reuteri</i>	forward ACCGAGAACCACCGGTTATTT, reverse CATAACTTAAC-CTAAACAATCAAAGATTGTCT



**Figure S1.** Dose-dependent activity of 3-IAld in vivo. C57BL/6 mice were infected with *Aspergillus* conidia and treated with 3-IAld at different doses intranasally. Fungal growth ( $\text{Log}_{10}$  CFU in the lung). Values represent the mean  $\pm$  SD of 6 mice per group. None, infected mice. \*  $p < 0.05$ ; \*\*  $p < 0.01$ , One-way ANOVA - Bonferroni's, treated vs None mice.



**Figure S2.** Lack of systemic toxicity and AhR activation in *Cfr*<sup>F508del/F508del</sup> mice administered with 3-IAld-PI. Mice received 4.5 mg/kg of 3-IAld directly delivered into the lung by pulmonary insufflation (PI) and evaluated for (A) signs of tissue pathology in the indicated organs 3 (early) and 7 (late) days later and (B) activation of AhR-target genes 24, 48 and 72 hours later. Photographs of PAS-stained sections were taken using a high-resolution Olympus DP71 microscope using an x10 objective. Scale bars, 100 (colon), 200 (ileum and liver), 400 (lung and spleen)  $\mu\text{m}$  and 1mm (kidney). (B) AhR-gene expression in total cells from the different organs by RT-PCR. Values represent the mean  $\pm$  SD of 2 mice per group. \*  $p < 0.05$ ; \*\*  $p < 0.01$ , treated versus untreated mice (None); One-way ANOVA - Bonferroni's.